Pancreatic Cell News 8.26 July 4, 2017 | |
| |
TOP STORYCompensatory Metabolic Networks in Pancreatic Cancers upon Perturbation of Glutamine Metabolism Scientists showed that despite marked early effects on in vitro proliferation caused by glutaminase inhibition, pancreatic cancer cells have adaptive metabolic networks that sustain proliferation in vitro and in vivo. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISMCL-1 Is a Key Anti-Apoptotic Protein in Human and Rodent Pancreatic β-Cells The authors report that MCL-1 downregulation is associated with cytokine-mediated killing of human β-cells, a process partially prevented by MCL-1 overexpression. By generating a β-cell specific Mcl-1 knockout mouse strain, they observed that, surprisingly, MCL-1 ablation does not affect islet development and function. [Diabetes] Abstract Keratins Regulate β-Cell Mitochondrial Morphology, Motility, and Homeostasis The mitochondrial network in primary cultured K8 knockout β-cells was more fragmented compared with K8+/+ mitochondria, correlating with decreased levels of mitofusin 2 and the mitofusin 2- and keratin-binding protein trichoplein. [FASEB J] Abstract Researchers showed that HBK001 could promote glucose-stimulated insulin secretion in mouse and human primary islets. A single administration of HBK001 in ICR mice could increase plasma incretins levels much more efficiently than linagliptin, a classic DPP4 inhibitor. [Sci Rep] Full Article Experiments in MIN-6 β-cells revealed that treatment with doxorubicin to directly induce DNA damage mimicked observed effects in islets. Islets from animals treated with pioglitazone concurrently with high fat diet (HFD) demonstrated a reversal of effects observed from HFD alone. [Sci Rep] Full Article Lineage Conversion of Mouse Fibroblasts to Pancreatic α-Cells α-like cells (iAlpha cells) possessed α-cell function in vitro and altered blood glucose levels in vivo. Transplantation of iAlpha cells into nude mice resulted in insulin resistance and increased β-cell proliferation. [Exp Mol Med] Full Article PANCREATIC CANCERResearchers used mouse models, genetically engineered to recapitulate human pancreatic cancer, and several pancreatic cancer cell lines as a model to investigate the effect of matrix stiffness in epithelial–mesenchymal transition and resistance to chemotherapeutics. [Oncogenesis] Full Article Studies with pitavastatin in primary patient derived tumor cells and established pancreatic ductal adenocarcinoma lines revealed dose dependent growth inhibition. [Oncotarget] Full Article Investigators found that RUNX2/mutant p53/TAp63-regulatory axis has a pivotal role in the determination of suberoylanilide hydroxamic acid (SAHA) sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells. [PLoS One] Full Article Researchers evaluated the possibility that modulation of nuclear factor E2 related factor-2 (NRF2) expression could be effective in the treatment of pancreatic cancer cells. They investigated whether the depletion of NRF2 by using small interfering RNAs was effective in the expression of biomarkers of pancreatic cancer stemness such as aldehyde dehydrogenase 1 family, member A1 (ALDH1A1) and aldehyde dehydrogenase 3 family, member A1 (ALDH3A1). [Antioxidants] Full Article | |
| |
REVIEWSThe authors follow the most central triggering pathway to insulin secretion from its very beginning when glucose enters the beta cell to the calcium oscillations it produces to trigger fusion of insulin containing granules with the plasma membrane. Along the way, they describe the crucial building blocks that contribute to the flow of information and focus on their functional role in mice and humans and on their translational implications. [Islets] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSBoston Biomedical, Inc. featured two oral and two poster presentations evaluating napabucasin in metastatic colorectal cancer and pancreatic adenocarcinoma. [Press release from Boston Biomedical, Inc. discussing research presented at European Society of Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer, Barcelona] Press Release Halozyme Phase II Data in Advanced Pancreas Cancer Presented Results from Halozyme Therapeutics Phase II randomized, multi-center clinical trial in pancreas cancer patients were shared in two oral presentations. [Press release from Halozyme, Inc. discussing research presented at European Society of Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer, Barcelona] Press Release ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer ARMO BioSciences, Inc. announced clinical data on its lead investigational immuno-oncology drug AM0010. [Press release from ARMO BioSciences, Inc. discussing research presented at European Society of Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer, Barcelona] Press Release | |
| |
INDUSTRY NEWSMinomic Clinical Study Progresses for Miltuximab in Prostate, Bladder, and Pancreatic Cancer Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of Miltuximab™, a chimeric version of Minomic’s MIL-38 anti-Glypican 1 antibody conjugated to the radioactive isotope 67Gallium. [Minomic International Ltd] Press Release NOXXON Pharma N.V. announced that the first patients were treated in its Phase I/II clinical trial in patients with metastatic colorectal and pancreatic cancer. [NOXXON Pharma N.V.] Press Release | |
| |
POLICY NEWSHouse Lawmakers Balk at Most Trump Science Cuts in Early Bills No. That’s the first official answer from lawmakers in the U.S. House of Representatives to President Donald Trump’s request to make deep budget cuts at several key science funding agencies. [ScienceInsider] Editorial Europe’s next Big Science-Funding Program Urged to Double Its Budget Midway through the European Union’s sprawling seven-year, €75-billion research-funding program known as Horizon 2020, scientists are already angling for more money and less red tape in its successor. [Nature News] Editorial Germany and Poland Launch Research ‘Twinning’ Effort Germany and Poland are to jointly fund top scientists to start research groups at Polish institutes, in a scheme that could provide a new blueprint for east–west research collaboration in the European Union. [Nature News] Editorial
| |
EVENTSNEW Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Integrative Computational Biology (Wellcome Trust Sanger Institute) Group Leader – Cancer Research (University of Lille) Postdoctoral Positions – Cancer Research (University of Minnesota) Postdoctoral Scholarship – Diabetes Research (Lund University) Postdoctoral Position – Pancreatic Cell Research (Inserm) Postdoctoral Research Fellow – Pancreatic Cancer (Fred Hutchinson Cancer Research Center) PhD Position – Health/Biomedical Sciences (University of Auckland) Postdoctoral Fellowship – Diabetes UK (Diabetes UK) PhD Studentship – Diabetes UK (Diabetes UK) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|